Follow The Filings

CVRX

Health Care, filed as CVRX INC (COM), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by CVRX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CVRX insider trades
  • $377K bought by 2 insiders
  • $797K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Brent Binkowski COO
    Buy
    $76K 26,223 shares at $2.91 +87% to stake
    Traded Aug 13 Filed Aug 13
    ↗
  2. Mudit K. Jain Director
    Buy
    $298K 46,800 shares at $6.36 +5% to stake
    Traded Feb 20 Filed Feb 23
    ↗
  3. Mudit K. Jain Director
    Buy
    $2,785 600 shares at $4.64 +12% to stake
    Traded Feb 18 Filed Feb 18
    ↗
  4. & Johnson Johnson 10% owner, +1 joint filer
    Sale
    $224K 22,337 shares at $10.03 0.6% of stake
    Traded Nov 25–26 Filed Jan 8
    ↗
  5. & Johnson Johnson 10% owner, +1 joint filer
    Sale
    $27K 2,700 shares at $10.05 0.1% of stake
    Traded Nov 21–24 Filed Nov 25, 2025
    ↗
  6. & Johnson Johnson 10% owner, +1 joint filer
    Sale
    $10K 1,000 shares at $10.00 <0.1% of stake
    Traded Nov 12, 2025 Filed Nov 14, 2025
    ↗
  7. & Johnson Johnson 10% owner, +1 joint filer
    Sale
    $536K 52,532 shares at $10.21 1.3% of stake
    Traded Nov 6–7 Filed Nov 10, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 14 stock grants and 6 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 21 shown.

Filed Form Detail Links
SCHEDULE 13D/A — Filing Doc
8-K 5.02,9.01 Filing Doc
SCHEDULE 13D — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,2.02,2.03,8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 15 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $39.3M $51.29M $56.65M
Gross profit $33.04M $42.96M $48.34M
Gross margin * 84.1% 83.8% 85.3%
Net income -$41.2M -$59.96M -$53.31M
Net margin * -104.8% -116.9% -94.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $112.09M $129.81M $101.65M
Total non-current assets * $3.14M $3.6M $3.15M
Total assets $115.23M $133.41M $104.79M
Total current liabilities $7.86M $10.76M $13.32M
Total non-current liabilities * $31.42M $51.6M $52.15M
Total equity $75.95M $71.06M $39.32M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$39.02M -$39.14M -$40.17M
Cash from investing -$0.591M -$1.36M -$0.58M
Cash from financing $23.98M $55.87M $10.52M
Net change in cash -$15.62M $15.36M -$30.22M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf